Amrutanjan Health Care Limited · NSE:AMRUTANJAN
Amrutanjan Health Care — FY2023 Earnings Presentation
18 slides from Amrutanjan Health Care's earnings presentation, Jun 1, 2023
Slide 1: Exchange filing cover letter for investor presentation
AHCL/ SE/ 13 /2023-24 June01, 2023 The National Stock Exchange of India Limited BSE Limited "Exchange Plaza", C-1, Block G Department of Corporate Services Bandra-Kurla Complex, Sandra (E) 1st Floor, Mumbai 400 051 P.J. Towers, Dalal Street, ISIN: INE098F01031 Mumbai 400 001 Symbol : AMRUTANJAN Scri
Slide 2: Amrutanjan Health Care Limited Investor Presentation
Amrutanjan Health Care Limited Investor Presentation - Quarter & Year Ended 31st March 2023 Date: 30th May 2023
Slide 3: Contents
Contents a. Business Update b. FY23 Performance c. Q4 FY23 Performance d. Way Forward Investor Presentation | Quarter and Year Ended 31st March 2023 2
Slide 4: Business Update
Business Update Investor Presentation | Quarter and Year Ended 31st March 2023 3
Slide 5: Business Update
Business Update Ø The pain management category has degrown quarter over quarter this past year but has regressed the lowest in Q4. We are hopeful that this is the bottom and that the category will go back to historical growth rates of 6 to 8% in FY 24. Ø Your company's core strategy continues to rem
Slide 6: FY23 Performance
FY23 Performance Investor Presentation | Quarter and Year Ended 31st March 2023 5
Slide 7: Financials – FY23
Financials – FY23 (Rs. in Crores) Gross Sales Profit Before Tax 455.85 426.22 90.58 53.65 FY23 FY22 FY23 FY22 Gross Sales - E Comm. Profit After Tax 10.85 67.19 9.55 39.83 FY23 FY22 FY23 FY22 Investor Presentation | Quarter and Year Ended 31st March 2023 6
Slide 8: Financials – FY23
Financials – FY23 (Rs. in Crores) Major reasons for reduction in Profit Before Tax : Particulars Amount Remarks Top Line reduction: Key Product 8 ML balm sales has Decrease in Gross Margin come down by 31.90 crs due to Sales reduction & Product Mix: Comfy sales has grown by 9.16 crs Product mix 25.3
Slide 9: Financials – FY23
Financials – FY23 (Rs. in Crores) Employee Benefit Expenses 48.81 48.23 FY23 FY22 Increase: 1.20% Advertisement & Selling Expenses Other Expenses 51.87 52.58 55.03 42.64 FY23 FY22 FY23 FY22 Decrease: 4.45% Increase: 21.65% Investor Presentation | Quarter and Year Ended 31st March 2023 8
Slide 10: Financials – FY23 – OTC Division
Financials – FY23 – OTC Division (Rs. in Crores) Gross Sales - OTC Notes: 416.73 385.70 • Key raw material prices (excluding Menthol crystal price) are higher when compared to FY22. • The prices of packing materials are FY23 FY22 higher when compared to FY22. The prices has marginally come down in G
Slide 11: Financials – FY23 – Beverage Division
Financials – FY23 – Beverage Division (Rs. in Crores) Gross Sales - Beverages 38.38 37.34 Notes: • Raw Material & Packing Material prices are higher when compared to FY23 FY22 FY22. Growth: 2.79% • Advertisement spend is at Rs. 5.33 cr for FY23 against Rs. 5.57 cr for Gross Sales - Electro Plus FY22
Slide 12: Key Financial Ratios
Key Financial Ratios Return on Capital Employed % Operating Profit Margin (%) 25.00% 22.44% 40.00% 34.83% 35.00% 20.00% 30.00% 14.15% 15.00% 25.00% 18.75% 20.00% 10.00% 15.00% 10.00% 5.00% 5.00% 0.00% 0.00% FY23 FY22 FY23 FY22 Debtors Turnover Ratio Inventory Turnover Ratio 16.00 14.52 20.00 18.68 1
Slide 13: Q4 FY23 Performance
Q4 FY23 Performance Investor Presentation | Quarter and Year Ended 31st March 2023 12
Slide 14: Financials – Q4 FY23
Financials – Q4 FY23 (Rs. in Crores) Gross Sales Profit before tax Profit after tax 124.37 20.02 14.71 115.80 16.47 12.70 Q4 FY23 Q4 FY22 Q4 FY23 Q4 FY22 Q4 FY23 Q4 FY22 Investor Presentation | Quarter and Year Ended 31st March 2023 13
Slide 15: Financials – Q4 FY23
Financials – Q4 FY23 (Rs. in Crores) Gross Sales - OTC Gross Sales - Comfy 19.46 108.94 97.37 18.66 Q4 FY23 Q4 FY22 Q4 FY23 Q4 FY22 Growth: 4.29% Gross Sales - Beverages Gross Sales – Electro Plus 14.33 17.84 12.93 14.83 Q4 FY23 Q4 FY22 Q4 FY23 Q4 FY22 Growth: 20.30% Growth: 10.83% Investor Presenta
Slide 16: Way Forward
Way Forward Investor Presentation | Quarter and Year Ended 31st March 2023 15
Slide 17: Way Forward
Way Forward We remain focused on executing our key priorities: • Expand distribution • Go global • Grow E-Commerce vertical • Costs reduction Investor Presentation | Quarter and Year Ended 31st March 2023 16
Slide 18: Investor Presentation | Quarter and Year Ended 31st March 2023
Investor Presentation | Quarter and Year Ended 31st March 2023 17
Amrutanjan Health Care — FY2023 Earnings Presentation on 6ix